October 2023

NEWS & COLUMNS

6-7 NEWS
Merck announces partnerships worth $1.3bn; Boehringer and Lilly’s Jardiance approved by MHRA

8-9 NEWS
UK rejoins Horizon Europe research initiative; FDA works to reduce cancer drug shortages

10-11 CORONAVIRUS NEWS
Moderna’s updated COVID-19 vaccine approved by MHRA; NHS starts winter vaccination programme early

12 DARWIN'S MEDICINE
A happy collision in market access

13 POLICY AND PUBLIC HEALTH
People are investing in longevity... and by ‘people’, I mean profit-seekers

14 DID SOMEBODY SAY AI?
Things are moving rapidly and we are currently only scratching the surface of AI’s possibilities

15 INNOVATIVE IMPACT BLOG
Building a behaviour change survival kit

FEATURES

16-17 PREPARING FOR THE CLINICAL TRIALS OF THE FUTURE
With access to more data than ever before, now is the time for the industry to modernise, become data-led and boost patient experience

18-20 NEUROMYELITIS OPTICA SPECTRUM DISORDER: IS THERE HOPE ON THE HORIZON?
The new science behind the management of this devastating rare autoimmune disease

22-23 THE IMPACT OF CELL THERAPIES ON CANCER TREATMENTS
PME talks to Matt Angel, CEO of Eterna Therapeutics, about how research using cell therapies to treat cancer has improved in the last decade, and how these therapies benefit patients

24-25 WORLD MENTAL HEALTH DAY: IF WE DON'T HEAL THE HEALERS, WHO WILL HEAL US?
Today we are witnessing the fastest deterioration of well-being in human history and HCPs are far from immune to this trend

16. Preparing for the clinical trials of the future